Targeting MIR155HG in glioma: a novel approach

Glioblastoma (GBM) is the most common adult brain tumor and the most aggressive of all gliomas. Despite maximum surgical resection followed by chemoradiation, the median survival of patients with GBM remains dismal at 12–15 months. High-throughput pancancer initiatives such as The Cancer Genome Atlas have helped us gain an increased understanding of the evolution and molecular landscape of GBM. This knowledge must ultimately be put to clinical use in order to improve outcome in patients. In this issue, Wu et al demonstrate how data mined from publicly available datasets combined with molecular docking can be used to understand the biology and targeting of microRNA-155 (miR-155).

http://ift.tt/2wXUnHx